Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accounts Payables (2021 - 2025)

Historic Accounts Payables for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $49.8 million.

  • ARS Pharmaceuticals' Accounts Payables rose 20124.08% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 20124.08%. This contributed to the annual value of $22.8 million for FY2024, which is 96039.93% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Accounts Payables stood at $49.8 million, which was up 20124.08% from $44.3 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Accounts Payables peaked at $49.8 million during Q3 2025, and registered a low of $126000.0 during Q3 2022.
  • Moreover, its 5-year median value for Accounts Payables was $4.9 million (2022), whereas its average is $11.8 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 9267.44% in 2022, then skyrocketed by 858650.79% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Accounts Payables (Quarter) stood at $3.1 million in 2021, then surged by 58.71% to $4.9 million in 2022, then crashed by 56.32% to $2.2 million in 2023, then surged by 960.4% to $22.8 million in 2024, then soared by 117.89% to $49.8 million in 2025.
  • Its last three reported values are $49.8 million in Q3 2025, $44.3 million for Q2 2025, and $27.0 million during Q1 2025.